Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138780 | 0.81 | ADORA2A (0.41) | TDO2ALDH1A1TP53MAPK1 | |
| SCHEMBL19917175 | 0.61 | PDE5A (0.35) | KMOTDO2NPC1ALDH1A1TP53 | |
| SCHEMBL19917015 | 0.60 | FFAR2 (0.39) | TDO2 | |
| SCHEMBL17603703 | 0.60 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6467183 | 0.58 | ADORA2A (0.68) | ALDH1A1TP53MAPK1SMN1; SMN2 | |
| SCHEMBL2795381 | 0.58 | USP7 (0.33) | — | |
| SCHEMBL6467180 | 0.57 | ADORA1 (0.44) | NPC1RAB9A | |
| SCHEMBL19900171 | 0.57 | NR1H4 (0.34) | — | |
| SCHEMBL31526106 | 0.57 | RET (0.36) | NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL20031502 | 0.56 | SMURF1 (0.37) | TDO2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | KMO 3244/4885S1PR3 4301/4885TDO2 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.